Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells ; volume:18 ; number:1 ; day:8 ; month:5 ; year:2018 ; pages:1-11 ; date:12.2018
BMC cancer ; 18, Heft 1 (8.5.2018), 1-11, 12.2018
- Creator
-
Molnár, Eszter
- Contributor
-
Rittler, Dominika
Baranyi, Marcell
Grusch, Michael
Berger, Walter
Döme, Balázs
Tóvári, József
Aigner, Clemens
Tímár, József
Garay, Tamás
Hegedus, Balazs
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-4455-x
- URN
-
urn:nbn:de:101:1-2018071323572818821979
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Molnár, Eszter
- Rittler, Dominika
- Baranyi, Marcell
- Grusch, Michael
- Berger, Walter
- Döme, Balázs
- Tóvári, József
- Aigner, Clemens
- Tímár, József
- Garay, Tamás
- Hegedus, Balazs
- SpringerLink (Online service)
Other Objects (12)
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
MEK + CDK4 a regimen for non-BRAF V6000 melanoma